Invivogen
Menu

InvivoGen's product citations

Citations

InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).

Citations search

You can search by ‘Product Name’ or ‘Year’.

Find a citation by product name
Enter a year of publication
Product Citation Year Journal Authors Page
SP600125 Tumor Necrosis Factor-alpha utilizes MAPK/NFκB pathways to induce cholesterol... 2021 PLoS One Pokharel S.M. et al. DOI: 10.1371/journal.pone.0257576
SB203580 Tumor Necrosis Factor-alpha utilizes MAPK/NFκB pathways to induce cholesterol... 2021 PLoS One Pokharel S.M. et al. DOI: 10.1371/journal.pone.0257576
NF-κB and NLRP3 inflammasome inhibitor - BAY 11-7082 Tumor Necrosis Factor-alpha utilizes MAPK/NFκB pathways to induce cholesterol... 2021 PLoS One Pokharel S.M. et al. DOI: 10.1371/journal.pone.0257576
Caspase-1 and Caspase-4 inhibitor SFTSV Infection Induced Interleukin-1β Secretion Through NLRP3 Inflammasome A... 2021 Front Immunol. Liu J.W. et al. DOI: 10.3389/fimmu.2021.595140
Nigericin SFTSV Infection Induced Interleukin-1β Secretion Through NLRP3 Inflammasome A... 2021 Front Immunol. Liu J.W. et al. DOI: 10.3389/fimmu.2021.595140
Puromycin Yes-Associated Protein Is Required for ZO-1-Mediated Tight-Junction Integrity... 2021 Biomedicines Kim S.Y et al. DOI: 10.3390/biomedicines9091264
NF-κB and NLRP3 inflammasome inhibitor - BAY 11-7082 Yes-Associated Protein Is Required for ZO-1-Mediated Tight-Junction Integrity... 2021 Biomedicines Kim S.Y et al. DOI: 10.3390/biomedicines9091264
THP1-Blue™ NF-κB Cells Chitin Glucan Shifts Luminal and Mucosal Microbial Communities, Improve Epith... 2021 Nutrients Calatayud M. et al. DOI: 10.3390/nu13093249
LPS-EK (LPS from E. coli K12) Chitin Glucan Shifts Luminal and Mucosal Microbial Communities, Improve Epith... 2021 Nutrients Calatayud M. et al. DOI: 10.3390/nu13093249
QUANTI-Blue™ Chitin Glucan Shifts Luminal and Mucosal Microbial Communities, Improve Epith... 2021 Nutrients Calatayud M. et al. DOI: 10.3390/nu13093249
LPS-EB (LPS from E. coli O111:B4) Endothelial Poldip2 regulates sepsis-induced lung injury via Rho pathway acti... 2021 Cardiovasc Res. Dolmatova E.V. et al. DOI: 10.1093/cvr/cvab295
QUANTI-Luc™ Intratumoral combination therapy with poly(I:C) and resiquimod synergisticall... 2021 J Immunother Cancer Anfra C. et al. DOI: 10.1136/jitc-2021-002408
THP1-Lucia™ NF-κB Cells Intratumoral combination therapy with poly(I:C) and resiquimod synergisticall... 2021 J Immunother Cancer Anfra C. et al. DOI: 10.1136/jitc-2021-002408
Imiquimod (R837) Intratumoral combination therapy with poly(I:C) and resiquimod synergisticall... 2021 J Immunother Cancer Anfra C. et al. DOI: 10.1136/jitc-2021-002408
Poly(I:C) LMW Intrauterine immunizations trigger antigen-specific mucosal and systemic immu... 2021 Vaccine Choudhary P. et al. DOI: 10.1016/j.vaccine.2021.08.080
IL-1α & IL-1β Reporter HEK 293 Cells Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients wit... 2021 Cell Discov. Xue L. et al. DOI: 10.1038/s41421-021-00299-6
IL-6 Reporter HEK 293 Cells Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients wit... 2021 Cell Discov. Xue L. et al. DOI: 10.1038/s41421-021-00299-6
R848 (Resiquimod) Siglec-H-Deficient Mice Show Enhanced Type I IFN Responses, but Do Not Develo... 2021 Front Immunol. Szumilas N. et al. DOI: 10.3389/fimmu.2021.698420
ODN 1585 - TLR9 ligand Siglec-H-Deficient Mice Show Enhanced Type I IFN Responses, but Do Not Develo... 2021 Front Immunol. Szumilas N. et al. DOI: 10.3389/fimmu.2021.698420
3'3'-cGAMP Siglec-H-Deficient Mice Show Enhanced Type I IFN Responses, but Do Not Develo... 2021 Front Immunol. Szumilas N. et al. DOI: 10.3389/fimmu.2021.698420

Pages

Customer Service
& Technical Support
Contact us
Shopping cart is empty